(Q42452796)

31 October 2017

title

The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin (English)

1 reference

31 October 2017

main subject

xeroderma pigmentosum

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

1 April 2024

author name string

B. Giannotti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616811

1 April 2024

L. Vanzi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616811

1 April 2024

E. M. Difonzo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616811

1 April 2024

N. Pimpinelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14616811

1 April 2024

language of work or name

1 reference

1 November 2003

1 reference

full work available at URL

31 October 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2230.28.s1.11.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2230.28.s1.11.x/fullpdf

1 April 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

Clinical and Experimental Dermatology

1 April 2024

published in

1 reference

31 October 2017

volume

28 Suppl 1

1 reference

31 October 2017

page(s)

33-35

1 reference

Xeroderma pigmentosum--bridging a gap between clinic and laboratory.

31 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

UV mutation signature in tumor suppressor genes involved in skin carcinogenesis in xeroderma pigmentosum patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

The genetics of the hereditary xeroderma pigmentosum syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.28.S1.11.X

Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome

1 April 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

The genetic basis of xeroderma pigmentosum and trichothiodystrophy syndromes

1 April 2024

12

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

1 April 2024

Nonmelanoma skin cancer

16

1 reference

https://api.crossref.org/works/10.1046/J.1365-2230.28.S1.11.X

1 April 2024

Identifiers

1 reference

31 October 2017

1 reference